Anal Cancer is an indication for drug development with over 90 pipeline drugs currently active. According to GlobalData, preregistered drugs for Anal Cancer have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Anal Cancer compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anal Cancer overview
Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity.
For a complete picture of PTSR and LoA scores for drugs in Anal Cancer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.